Can venetoclax/venetoclax be used together with posaconazole?

Venetoclax/Venetoclax is a targeted drug used to treat certain types of hematological malignancies. It mainly works by selectively inhibiting the B-cell lymphoma 2 (BCL-2) protein. Posaconazole is a broad-spectrum antifungal drug mainly used to prevent and treat invasive fungal infections, especially in immunocompromised patients. Because these two drugs may interact during treatment, their combined use is generally not recommended.

From the perspective of drug metabolism, posaconazole is a potent inhibitor of cytochromeP450 3A4 (CYP3A4), and venetoclax is also considered a substrate of CYP3A4. This means that posaconazole can significantly inhibit the metabolism of venetoclax, resulting in an increase in its plasma concentration. This drug-drug interaction may trigger a range of adverse effects, particularly an increased risk of tumor lysis syndrome (TLS). Tumor lysis syndrome is a complex pathological condition caused by the rapid breakdown of cancer cells that can lead to hyperuricemia, renal failure, electrolyte imbalance, and other serious consequences.

Clinical studies have shown significant changes in the pharmacokinetic parameters of venetoclat when used concomitantly with posaconazole. For example, when 500 mg of venetoclat is combined with posaconazole, the maximum plasma concentration (Cmax) and the area under the curve (AUC0-24) within 24 hours are significantly increased, which indicates that the exposure level of venetoclat in the body increases. Specific study results pointed out that the Cmax and AUC0-24 of venetoclax increased by 53% to 93% and 76% to 155%, respectively. This significant increase in drug concentration will undoubtedly increase the risk of adverse reactions and may also affect the prediction and management of treatment effects.

In addition, side effects of venetoclax include nausea, vomiting, diarrhea, and fatigue, and these adverse reactions may be more obvious when the drug is used in combination. At the same time, the drug's suppressive effect on bone marrow may also increase, leading to a decrease in blood cell counts, which may lead to complications such as anemia, bleeding, and infection. Therefore, in clinical applications, for patients who require concurrent use of venetoclat and posaconazole, individual risks must be carefully assessed and a dose reduction of venetoclat should be considered to mitigate the possible risk of interaction.

In summary, the combined use of venetoclax with posaconazole without adequate monitoring and appropriate dose adjustment is not recommended. In actual clinical practice, if a patient really needs to receive treatment with these two drugs at the same time, it must be done under the guidance of professional medical personnel, and the dosage must be carefully adjusted and monitored according to the patient's specific condition to ensure the patient's safety and therapeutic effect. In this context, doctors need to closely monitor the patient's physiological status and possible side effects, and constantly adjust the treatment plan to achieve the best treatment effect.

Reference materials:https://www.drugs.com/drug-interactions/posaconazole-with-venetoclax-1902-0-3745-0.html